Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
Clinical trial NCT02679170 · COMPLETED
Trial details
- NCT number
- NCT02679170
- Sponsor
- Pfizer
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2016-06-29
- Primary completion
- 2022-05-04
- Enrollment
- 692
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.